{"entity":{"id":"nct03435796","kind":"trial","name":"Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells","aka":[],"tldr":"A phase 2/3 trial of Gene-modified (GM) T cell therapy in advanced solid tumours, run by Celgene, now recruiting.","summary":"Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells is a phase 2/3 interventional study registered as NCT03435796 by Celgene, with 1541 participants planned, started 2018-07-19 and due to reach its primary completion in 2036-11-30. Interventions recorded: Gene-modified (GM) T cell therapy.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT03435796","url":"https://clinicaltrials.gov/study/NCT03435796"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["bms"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT03435796","phase":"2/3","setting":"Long-Term Follow-up Protocol for Subjects Treated With Gene-Modified T Cells","sponsor":"Celgene","enrolled":1541,"outcomes":[]},"route":"/trials/nct03435796/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"company":[{"id":"bms","kind":"company","name":"Bristol Myers Squibb","route":"/companies/bms/"}]}}